YOLFTbeta
69

Prince Pharmaceutical Co., Ltd.

6935 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

27.10TWD-1.05 (-3.73%)

Price History

Full chart

Market Stats

Previous Close28.15
Open26.85
Day Range26.80 – 27.55
52-Week Range25.80 – 33.68
Volume11.07K
Market Cap1.35B
P/E (TTM)8.20
Forward P/E0.00
EPS3.47
Dividend Yield1.74%
Beta0.61
50-Day Avg29.04
200-Day Avg29.44

About

Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin C tablets, vitamin B film-coated tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yunlin, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODa Li
  • Employees216
  • HeadquartersNo.168, Keyun S. Road, Yunlin, Taiwan, 632, Taiwan
  • Websitehttps://www.prince-pharm.com.tw

Leadership

  • Da LiGM & Chairman
  • Cuiwei ChenAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue249.61M295.79M441.08M712.53M753.33M690.02M1.06B
Growth (%)-+18.50%+49.12%+61.54%+5.73%-8.40%+53.07%
Cost of Revenue182.02M206.82M315.59M506.74M600.23M615.75M833.65M
Gross Profit67.59M88.98M125.49M205.79M153.09M74.28M222.55M
Gross Margin27.08%30.08%28.45%28.88%20.32%10.76%21.07%
Operating Expense76.89M139.26M126.60M137.95M127.41M123.63M111.67M
Operating Income-9.30M-50.28M-1.11M67.85M25.68M-49.35M110.88M
Operating Margin-3.73%-17.00%-0.25%9.52%3.41%-7.15%10.50%
EBITDA11.89M-7.77M43.47M125.58M88.19M20.68M175.94M
EBITDA Margin4.76%-2.63%9.86%17.62%11.71%3.00%16.66%
Net Income9.00K-33.80M-8.30M51.55M15.31M-53.54M96.32M
Net Income Margin0.00%-11.43%-1.88%7.24%2.03%-7.76%9.12%
R&D28.54M78.22M79.21M72.05M54.67M48.20M34.64M
R&D as % of Total Revenue11.44%26.44%17.96%10.11%7.26%6.99%3.28%
Interest Expense2.58M5.31M7.55M8.94M10.46M10.27M9.58M
Interest Expense % of Total Revenue1.03%1.79%1.71%1.25%1.39%1.49%0.91%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.16B1.21B1.29B1.30B1.41B1.35B1.50B
Total Liabilities536.89M604.10M687.77M645.91M636.47M626.19M664.81M
Total Equity619.62M610.77M602.87M658.38M774.47M722.06M838.67M
Cash175.05M57.08M72.50M71.96M122.57M102.80M152.62M
Total Debt475.68M524.97M565.99M523.11M490.36M460.80M-
Net Debt300.63M467.89M493.49M451.15M367.79M357.99M144.65M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow8.05M-212.00K42.36M91.65M62.50M46.21M90.06M
Investing Cash Flow-151.65M-186.90M-38.79M-40.02M-68.01M-17.32M-
Financing Cash Flow172.67M69.13M11.86M-52.17M56.11M-48.65M-
Capital Expenditure182.68M186.78M41.28M19.81M62.24M18.00M18.80M
Free Cash Flow-174.62M-186.99M1.08M71.84M256.00K28.21M71.25M
Dividends Paid----5.43M9.15M-
FCF to OCF-2168.15%88202.36%2.55%78.39%0.41%61.05%79.12%
Dividend Paid to FCF----2120.70%32.44%-

Key Statistics & Ratios

Market Cap1.35B
Enterprise Value1.53B
Trailing P/E8.20
Forward P/E0.00
Price / Sales1.10
Price / Book1.55
EPS3.47
Book Value23.30
Revenue (TTM)1.22B
Gross Profit (TTM)266.13M
EBITDA203.29M
Profit Margin10.62%
Operating Margin10.88%
Return on Equity16.14%
Return on Assets6.35%
Shares Outstanding47.41M
Shares Float12.47M
Beta0.61
Dividend Yield1.74%
Dividend Rate0.50
Payout Ratio14.27%

Dividends

20261×
0.50Jul 1, 2026
20241×
0.25Jun 21, 2024
20231×
0.15Jun 16, 2023